FilingReader Intelligence
China Resources Pharmaceutical subsidiaries report mixed H1 results
August 15, 2025 at 10:59 AM UTC•By FilingReader AI
China Resources Pharmaceutical Group announced interim results for two subsidiaries for the six months ended 30 June 2025.
KPC Pharmaceuticals reported revenue of 3.35bn yuan, down 11.68% year-on-year, with net profit falling 26.88% to 198.4m yuan.
Tasly Pharmaceutical Group recorded revenue of 4.29bn yuan, declining 1.91%, but net profit jumped 16.97% to 774.7m yuan.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
HKEX:3320•Hong Kong Exchange
News Alerts
Get instant email alerts when China Resources Pharmaceutical Group publishes news
Free account required • Unsubscribe anytime